EFGARTIGIMOD ALFA, JNJ-80202135
80202135MYG3002
Phase 3 small_molecule active
Quick answer
EFGARTIGIMOD ALFA, JNJ-80202135 for generalized myasthenia gravis is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- generalized myasthenia gravis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active